| 000 | 01744 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514191637.0 | ||
| 264 | 0 | _c20040830 | |
| 008 | 200408s 0 0 eng d | ||
| 022 | _a1462-0324 | ||
| 024 | 7 |
_a10.1093/rheumatology/keh248 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVoulgarelis, M | |
| 245 | 0 | 0 |
_aCombined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _cAug 2004 |
||
| 300 |
_a1050-3 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntigens, CD _xanalysis |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aB-Lymphocytes _ximmunology |
| 650 | 0 | 4 |
_aCryoglobulinemia _xetiology |
| 650 | 0 | 4 |
_aCyclophosphamide _xadverse effects |
| 650 | 0 | 4 |
_aDoxorubicin _xadverse effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, B-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrednisone _xadverse effects |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aSjogren's Syndrome _xcomplications |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xadverse effects |
| 700 | 1 | _aGiannouli, S | |
| 700 | 1 | _aAnagnostou, D | |
| 700 | 1 | _aTzioufas, A G | |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 43 _gno. 8 _gp. 1050-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/keh248 _zAvailable from publisher's website |
| 999 |
_c14894329 _d14894329 |
||